参考文献/References:
[1]Biron CA,Gazzinellei RT.Effects of IL-12 on immune responses to microbial in-fections:a key mediator in regulating disease outcome[J].Curr Opin Immunol,1995(7):485-496. [2]Zwirner NW,Ziblat A.Regulation of NK Cell Activation and Effector Functions by the IL-12 Family of Cytokines:The Case of IL-27[J].Front Immunol,2017(8):25. [3]Chiu TL,Lin SZ,Hsieh WH,et al.AAV2-mediated interleukin-12in the treatment of malignant brain tumors through activation of NK cell[J].Int J Oncol,2009,35(6):1361-1367． [4]Canton DA,Shirley S,Wright J,et al.Melanoma treatment with intratumoral electroporation of tavokinogene telseplasmid(pIL-12,tavokinogene telseplasmid)[J].Immunotherapy,2017(9):1309-1321. [5]Wang P,Li X,Wang J,et al.Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent[J].Nat Commun,2017,8(1):1395. [6]Zhou ZF,Peng F,Li JY,et al.Intratumoral IL-12 Gene Therapy Inhibits Tumor Growth In A HCC-Hu-PBL-NOD/SCID Murine Model[J].Onco Targets Ther,2019(12):7773-7784. [7]Parhar Ranjit S,Zou Minjing,Al-Mohanna Futwan A,et al.IL-12 immunotherapy of Braf(V600E)-induced papillary thyroid cancer in a mouse model[J].Laboratory Investigation,2016,96(1):89-97. [8]Mukhopadhyay A,Wright J,Shirley S,et al.Characterization of abscopal effects of intratumoral electroporation-mediated IL-12 gene therapy[J].Gene Ther,2019,26(1-2):1-15. [9] Kueberuwa G,Kalaitsidou M,Cheadle E,et al.CD19 CAR T Cells Expressing IL-12 Eradicate Lymphoma in Fully Lymphoreplete Mice through Induction of Host Immunity[J].Mol Ther Oncolytics,2017(8):41-51. [10]Gao P,Zhang C,Bian X,et al.The increasingly anti-tumor effect of a colonic carcinoma DNA vaccine carrying HER2 by the adjuvanticity of IL-12[J].Journal of Immunopharmacology,2016,38(6):441-446. [11]Leverkus M,Walczak H,McLellan A,et al.Maturation of dendritic cells leads to up-regulation of cellular FLICE-in-hibitory protein and concomitant down-regulation of death ligand-mediated apoptosis[J].Blood,2000,96(7):2628-2631. [12]刁智娟.肿瘤坏死因子相关凋亡诱导配体的免疫调节功能研究[D].北京协和医学院,2010. [13]Beyer K,Normann L,Sendler M,et al.TRAIL Promotes Tumor Growth in a Syngeneic Murine Orthotopic Pancreatic Cancer Model and Affects the Host Immune Response[J].Pancreas,2016,45(3):401-408. [14]Huang M,Zhu H,Yi C,et al.A novel TRAIL mutant-TRAIL-Mu3 enhances the antitumor effects by the increased affinity and the up-expression of DR5 in pancreatic cancer[J].Cancer Chemother Pharmacol,2018,82(5):829-838. [15]Wu LS,Wang XW,He W,et al.TRAIL inhibits platelet-induced colorectal cancer cell invasion[J].J Int Med Res,2019,47(2):962-972. [16]Dai H,Jiang Y,Luo Y,et al.Triptolide enhances TRAIL sensitivity of pancreatic cancer cells by activating autophagy via downregulation of PUM1[J].Phytomedicine,2019(62):152953. [17]You C,Sun Y,Zhang S,et al.Trichosanthin enhances sensitivity of non-small cell lung cancer(NSCLC) TRAIL-resistance cells[J].Int J Biol Sci,2018,14(2):217-227. [18]Thapa B,Kc R,Bahniuk M,et al.Breathing New Life into TRAIL for Breast Cancer Therapy:Co-Delivery of pTRAIL and Complementary siRNAs Using Lipopolymers[J].Hum Gene Ther,2019,30(12):1531-1546. [19]冯忻,王彩霞,欧志英.重组人TRAIL蛋白联合顺铂对人卵巢癌细胞生长及凋亡的影响[J].中国癌症杂志,2016,26(8):648-654. [20]王宏艳,常瑛.重组可溶性TRAIL联合化疗药诱导急性白血病细胞凋亡[J].首都医科大学学报,2008(3):364-368.